"Baixinan-B(02185): National Medical Products Administration approves registration of BIOHEART Bioabsorbable Drug Eluting Stent"

Smart Financial News APP, Baixinan-B (02185) announced that on June 29, 2029, the Bioheart bioresorbable drug-eluting stent (BRS) developed independently by the company has been approved by the National Medical Products Administration of the People's Republic of China (NMPA) for the treatment of ischemic heart disease patients caused by native coronary artery lesions, in order to improve the diameter of the coronary artery lumen. The detailed results of the Bioheart BRS pivotal trial have been published in "JACC: Cardiovascular Interventions" (Volume 18, No. 1, 2025).